Zobrazeno 1 - 6
of 6
pro vyhledávání: '"C Bruce Mousseau"'
Publikováno v:
PLoS Pathogens, Vol 17, Iss 1, p e1009124 (2021)
Mycobacterial pathogens pose a sustained threat to human health. There is a critical need for new diagnostics, therapeutics, and vaccines targeting both tuberculous and nontuberculous mycobacterial species. Understanding the basic mechanisms used by
Externí odkaz:
https://doaj.org/article/cb022204bac0483da6f50be590b30e82
Autor:
Vidhyadhar Nandana, Imalka W. Rathnayaka-Mudiyanselage, Nisansala S. Muthunayake, Ali Hatami, C. Bruce Mousseau, Luis A. Ortiz-Rodríguez, Jamuna Vaishnav, Michael Collins, Alisa Gega, Kaveendya S. Mallikaarachchi, Hadi Yassine, Aishwarya Ghosh, Julie S. Biteen, Yingxi Zhu, Matthew M. Champion, W. Seth Childers, Jared M. Schrader
Publikováno v:
Cell Reports, Vol 42, Iss 10, Pp 113229- (2023)
Summary: Bacterial ribonucleoprotein bodies (BR-bodies) are non-membrane-bound structures that facilitate mRNA decay by concentrating mRNA substrates with RNase E and the associated RNA degradosome machinery. However, the full complement of proteins
Externí odkaz:
https://doaj.org/article/f3cd7f40f4024e329d89af5f71de7004
Autor:
Bonnie Jaskowski Huge, Devin North, C. Bruce Mousseau, Kyle Bibby, Norman J. Dovichi, Matthew M. Champion
Publikováno v:
Scientific Reports. 12
Public health efforts to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic rely on accurate information on the spread of the disease in the community. Acute and surveillance testing has been primarily used to character
Autor:
Matthew M. Champion, Patricia A. DiGiuseppe Champion, Kathleen R. Nicholson, C. Bruce Mousseau
Publikováno v:
PLoS Pathogens, Vol 17, Iss 1, p e1009124 (2021)
PLoS Pathogens
PLoS Pathogens
Mycobacterial pathogens pose a sustained threat to human health. There is a critical need for new diagnostics, therapeutics, and vaccines targeting both tuberculous and nontuberculous mycobacterial species. Understanding the basic mechanisms used by
Publikováno v:
Analytical Chemistry. 90:1423-1430
For a patient with metastatic colorectal cancer there are limited clinical op-tions aside from chemotherapy. Unfortunately, the development of new chemot-herapeutics is a long and costly process. New methods are needed to identify promising drug cand